Compare ONEW & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | IMUX |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 209.2M |
| IPO Year | 2019 | 2013 |
| Metric | ONEW | IMUX |
|---|---|---|
| Price | $11.83 | $16.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $16.50 | ★ $36.00 |
| AVG Volume (30 Days) | 105.6K | ★ 149.7K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $4.34 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.51 |
| 52 Week High | $17.53 | $17.43 |
| Indicator | ONEW | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 55.93 |
| Support Level | $11.31 | $0.75 |
| Resistance Level | $12.12 | $17.43 |
| Average True Range (ATR) | 0.70 | 1.05 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 43.17 | 60.71 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.